[Research progress on chemokine receptor 5-targeted therapy for HIV-1]
Abstract:
Along with the spread of human immunodeficiency virus 1 (HIV-1) infection in the world and the emergence of drug-resistant viral strains, it is urgent to seek the novel potent therapies. Chemokine receptor 5 (CCR5) is one of the main coreceptors involved in the entry of HIV-1 into target cells. Nowadays, a number of CCR5 antagonists have been developed and some of them have progressed to clinical trials or been approved. Research progress has also been made in the CCR5-targeted gene therapy. This review summarizes the recent research progress on the CCR5-targeted drug and gene therapy.
Insights
Novel therapies targeting the CCR5 receptor are crucial for combating HIV-1 infection and drug resistance. This review covers recent advancements in CCR5-targeted drug and gene therapies for effective treatment.
Area of Science:
- Virology and Immunology
- Drug Discovery and Development
- Gene Therapy
Context:
- The global spread of human immunodeficiency virus 1 (HIV-1) necessitates new therapeutic strategies.
- Emergence of drug-resistant HIV-1 strains poses a significant clinical challenge.
- Chemokine receptor 5 (CCR5) is a key co-receptor for HIV-1 entry into host cells.
Purpose:
- To review recent research progress in CCR5-targeted therapies for HIV-1.
- To highlight advancements in both pharmacological and genetic approaches.
Summary:
- CCR5 antagonists represent a promising class of drugs, with several candidates in clinical trials or already approved.
- Significant progress has been achieved in developing CCR5-targeted gene therapies.
- This review consolidates current knowledge on these therapeutic avenues.
Impact:
- Provides an overview of cutting-edge HIV-1 treatment options.
- Informs researchers and clinicians about the potential of CCR5-targeted interventions.
- Contributes to the ongoing search for more effective HIV-1 therapies.
